Skip to main content
QDELQuidelOrtho CorporationSell5.0·$9.87
SellModerate Confidence
Investment thesis

QuidelOrtho is an attractively valued diagnostics company with a forward P/E of 6.0x and a strong recent earnings track record, but high short interest of 24%, declining revenue of -10%, and a market cap below the $1 billion investable threshold create significant headwinds that must be resolved before the value opportunity can be realized.

Thesis pillars

  • Below Investable Market Cap↑Improving
  • Deep Value Forward Pe↑Improving
  • Earnings Beat Streak Recovery→Stable
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 3, 2026, based on the 10-K filed Feb 19, 2026· older than 90 days

Full reasoning →

Open full analysis

QuidelOrtho Corporation (QDEL) Stock Analysis

Oversold Bounce setup · Inst Constrain edge

SellVALUE-TRAP 1/5ValueGrowthShortModerate Confidence

Healthcare · Medical Devices

Sell if holding. Engine safety override at $9.87: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Below-average business quality; Negative price momentum.

QuidelOrtho develops and sells in-vitro diagnostic instruments and tests across four business units — Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine — serving customers in more than 140 countries through direct sales and distributors. Respiratory... Read more

$9.87+29.2% A.UpsideScore 5.0/10#47 of 62 Medical Devices
QualityF-score5 / 9FCF yield41.97%
Stop $9.53Analyst target $12.75(−15% haircut)A.R:R 1.9:1
Analyst consensus$15.00+52.0%3 analysts with price targets
$12.75Analyst target
$9.87price
$15.00mean
$20

Sell if holding. Engine safety override at $9.87: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Below-average business quality; Negative price momentum. Chart setup: Oversold RSI 30, near Bollinger lower, volume surge. Score 5.0/10, moderate confidence.

Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

No fresh coverage since Nov 3, 2026

Recent Developments — QuidelOrtho Corporation

Latest item Nov 3, 2026 · Generated 2026-11-18T11:57:28Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Feb 10, 202784d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Supplier: single and sole source suppliers
Quality below floor (2.8 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)7.5
Mkt Cap$677M
EV/EBITDA7.8
Profit Mgn-14.2%
ROE-19.3%
Rev Growth-11.6%
Beta0.80
DividendNone
Analysts with ratings8

Quality Signals

Piotroski F5/9

Options Flow

P/C0.29bullish
IV254%elevated

Concentration Risks(10-K Item 1A)

  • LOWProductrespiratory products15%
    10-K Item 1A: 'sales of our respiratory products accounted for approximately 15% of our total revenues for the year ended December 28, 2025'
  • HIGHSuppliersingle and sole source suppliers
    10-K Item 1A: 'our reliance on a small number of contract manufacturers and a large number of single and sole source suppliers'
  • MEDIUMCustomerkey distributors
    10-K Item 1A: 'we rely on certain key distributors for the sales of some of our products'

Material Events(8-K, last 90d)

  • 2026-06-23Item 5.02MEDIUM
    Board appointed Micah Young as CFO effective July 6, 2026, succeeding Joseph M. Busky, who previously announced plans to retire (disclosed February 13, 2026). Busky continues in his role through the effective date under a transition and retirement agreement.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Unprofitable operations — net margin -14.2%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Net Margin
0.0
Operating Margin
0.1
Moat
3.2
Gross Margin
4.9
Current Ratio
5.1
Piotroski F
5.6
Fcf Quality
6.0
FCF-positive but moderate margins (FCF margin 11%, FCF yield 42.0%)No competitive moatQuality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
1.0
Vol Acceleration
2.1
Rsi
3.0
Volume
10.0
Capitulation risk (RSI 30, below 200MA)Volume distribution (falling OBV)Below 200-MA, MA slope -14.7%/30d — confirmed downtrendVolume surge (2.9x avg) on selloff

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
0.0
Quality Rank
2.7
Value Rank
9.8
GatesMomentum 2.9<4.5Death cross (50MA < 200MA)Executive change: officer departure/appointmentA.R:R 1.9 ≥ 1.5Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 84d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEAROversold BounceSuitability: Speculative
RSI
30 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $9.82Resistance $14.85

Price Targets

$10
$13
A.Upside+29.2%
A.R:R1.9:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (2.8 < 4.0)
! momentum at 2.9 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
M
3/4 beats
Next Earnings2027-02-10 (84d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is QDEL stock a buy right now?

Sell if holding. Engine safety override at $9.87: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Below-average business quality; Negative price momentum. Chart setup: Oversold RSI 30, near Bollinger lower, volume surge. Prior stop was $9.53. Score 5.0/10, moderate confidence.

What is the QDEL stock price target?

Analyst target: $12.75 (+29.2% upside). Prior stop was $9.53. Stop-loss: $9.53.

What are the risks of investing in QDEL?

Concentration risk — Supplier: single and sole source suppliers; Quality below floor (2.8 < 4.0).

Is QDEL overvalued or undervalued?

QuidelOrtho Corporation trades at a P/E of N/A (forward 7.5). TrendMatrix value score: 9.2/10. Verdict: Sell.

What do analysts say about QDEL?

8 analysts rate QDEL, with a consensus score of 2.4/5. 3 analysts publish price targets averaging $15.

What does QuidelOrtho Corporation do?QuidelOrtho develops and sells in-vitro diagnostic instruments and tests across four business units — Labs, Molecular...

QuidelOrtho develops and sells in-vitro diagnostic instruments and tests across four business units — Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine — serving customers in more than 140 countries through direct sales and distributors. Respiratory diagnostics products, including the QuickVue and Sofia platforms, accounted for approximately 15% of total revenue in fiscal 2025, while the company winds down its U.S. donor-screening portfolio, expected substantially complete by the first half of 2026.

Related stocks: DCTH (Delcath Systems, Inc.) · BWAY (Brainsway Ltd.) · SENS (Senseonics Holdings, Inc.) · MASS (908 Devices Inc.) · TCMD (Tactile Systems Technology, Inc)
Home › Stocks › QDEL

Latest news

Latest News

Benzinga15d agoEarnings
Fiscal.ai15d agoRestructuring
Fiscal.ai15d ago
Benzinga15d agoRestructuring
Benzinga15d agoEarnings
Benzinga15d agoEarnings
Fiscal.ai20d ago
Fiscal.ai29d ago
Benzinga36d agoEarnings
Benzinga103d ago
Benzinga103d ago
Benzinga103d ago
Benzinga103d ago
Benzinga103d ago
Benzinga104d ago
Benzinga104d agoEarnings
Benzinga104d ago
Benzinga133d agoAnalyst
Benzinga140d agoAnalyst
Benzinga142d ago
Loading more...